Endocrinology Part 2

📚 02 Pediatric Superspecialities • 🎯 64 High-Yield MCQs • Nelson 22nd Edition Standard

Lipid Metabolism & Dyslipidemia Pharmacotherapy

  • Ezetimibe Mechanism & Indication: ((((ENDO2001)) · ((ENDO2002)))): Ezetimibe reduces plasma LDL-C by blocking sterol (cholesterol and plant sterol) absorption in enterocytes, leading to an upregulation of hepatic LDL receptors. It is indicated for elevated LDL cholesterol and does not decrease triglyceride levels.
  • Triglyceride-Lowering Drugs: ((ENDO2002)): Nicotinic acid (decreases VLDL production), fibrates (increase VLDL degradation and Apo A-1), and fish oils (omega-3 fatty acids decreasing hepatic TG synthesis) all lower triglycerides, whereas ezetimibe does not.
  • Novel Lipid-Lowering Agents: ((ENDO2003)): Mipomersen is a subcutaneous antisense oligonucleotide targeting apolipoprotein B (apoB) mRNA to reduce VLDL and LDL synthesis in homozygous familial hypercholesterolemia. Lomitapide inhibits microsomal triglyceride transfer protein (MTP), carrying a side effect of hepatic fat deposition.
  • Familial Chylomicronemia (Type I Hyperlipoproteinemia): ((ENDO2004)): Characterized by severely elevated triglycerides (>1000 mg/dL) due to lipoprotein lipase (LPL) or Apo C-II deficiency, presenting in childhood with eruptive xanthomas, lipemia retinalis, recurrent pancreatitis, and hepatosplenomegaly.
  • Apolipoprotein A (ApoA): ((ENDO2005)): Major structural protein of HDL; activates lecithin–cholesterol acyltransferase (LCAT) for reverse cholesterol transport. (Note: LDL and VLDL primarily contain ApoB-100; chylomicrons contain ApoB-48).

Bone, Calcium, and Rickets Disorders

  • Vitamin D–Dependent Rickets (VDDR) Types: ((ENDO2006)): VDDR type 2A results from mutations in the VDR gene (vitamin D receptor) and is classically associated with alopecia (50–70% of cases). VDDR type 1A results from mutations in CYP27B (renal 1$\alpha$-hydroxylase deficiency).
  • Hypophosphatemic Rickets Pathophysiology: ((((ENDO2007)) · ((ENDO2009)))): - Autosomal dominant hypophosphatemic rickets (ADHR) is caused by mutations in FGF23 preventing its protease degradation, leading to excess FGF23, renal phosphate wasting, and low 1,25-D. - X-linked hypophosphatemic rickets (XLH) is caused by mutations in PHEX. - Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is caused by mutations in SLC34A3 (sodium-phosphate co-transporter), resulting in high 1,25-D and hypercalciuria; calcitriol is contraindicated.
  • Hypercalcemia of Vitamin D Intoxication: ((ENDO2008)): Treated with glucocorticoids (blocks intestinal calcium absorption via 1,25-D antagonism) and hyperhydration. Cinacalcet has no role because vitamin D toxicity is non-PTH-mediated (PTH is suppressed).
  • Osteogenesis Imperfecta (OI): ((ENDO2010)): Classical OI (Sillence types 1–4) is caused by structural or quantitative defects in type I collagen (composed of two $\alpha$1(I) and one $\alpha$2(I) chains with Gly-X-Y repeats).

Syndromes, Obesity, and Hypoglycemia

  • ROHHAD vs. CCHS: ((((ENDO2011)) · ((ENDO2020)))): - Congenital Central Hypoventilation Syndrome (CCHS) presents in newborns/infants, lacks obesity/hypothalamic dysfunction, and is caused by PHOX2B mutations. - ROHHAD (Rapid onset obesity, hypothalamic dysfunction, hypoventilation, autonomic dysfunction) features rapid obesity, neuroblastic tumors (~50%), and CSF inflammatory markers, while lacking PHOX2B mutations.
  • Alström Syndrome: ((ENDO2012)): Autosomal recessive (ALMS1) presenting with childhood obesity, cone-rod dystrophy (retinitis pigmentosa), sensorineural hearing loss, dilated cardiomyopathy, and hypogonadism. (Distinguished from Bardet-Biedl by the absence of polydactyly and prominent cardiomyopathy/hearing loss).
  • Orexigenic vs. Anorexigenic Peptides: ((ENDO2013)): Ghrelin (secreted by stomach/duodenum) is the sole peripherally produced orexigenic (appetite-stimulating) peptide. Leptin and peptide YY signal satiety.
  • Congenital Hyperinsulinism: ((((ENDO2014)) · ((ENDO2015)))): Diagnosed by an inappropriate glycemic response to glucagon (plasma glucose rises >30 mg/dL during hypoglycemia). The very first physiologic defense against fasting hypoglycemia is a decrease in insulin secretion.

Thyroid Disorders and Polyendocrine Syndromes

  • Acquired Hypothyroidism in Children: ((((ENDO2016)) · ((ENDO2017)))): Slowing of linear growth is usually the earliest clinical manifestation but frequently goes unrecognized. Severe hypothyroidism with a small thyroid gland in autoimmune thyroiditis is mediated by TSH receptor-blocking antibodies.
  • Endemic Cretinism Forms: ((ENDO2018)): Myxedematous endemic cretinism (severe iodine deficiency) is distinguished from the neurologic form by delayed growth, delayed puberty, myxedema, absent goiter, and thyroid atrophy.
  • IPEX Syndrome: ((ENDO2019)): Caused by loss-of-function variants in FOXP3, leading to regulatory T-cell failure, early-onset type 1 diabetes mellitus, autoimmune enteropathy, and eczematous dermatitis.
  • Polyglandular Autoimmune Syndromes: ((ENDO2030)): Schmidt syndrome = Autoimmune Addison disease + autoimmune thyroid disease (APS type 2). Carpenter syndrome = Autoimmune Addison disease + type 1 diabetes mellitus.

Adrenal Disorders and Mineralocorticoid Regulation

  • X-Linked Adrenoleukodystrophy: ((ENDO2023)): Caused by pathogenic variants in ABCD1 (peroxisomal transporter for very-long-chain fatty acids), presenting with cerebral white-matter demyelination and primary adrenal insufficiency (distinguished from Zellweger spectrum/neonatal ALD which are AR).
  • CAH Mineralocorticoid Adequacy: ((ENDO2024)): In salt-wasting 21-hydroxylase deficiency, plasma renin activity (PRA) must be monitored; persistently suppressed PRA indicates excessive mineralocorticoid replacement requiring dose reduction.
  • Glucocorticoid-Remediable Aldosteronism (GRA / Type I FH): ((ENDO2025)): Autosomal dominant early-onset hypertension caused by a CYP11B1/CYP11B2 chimeric gene under ACTH control, characterized by elevated 18-hydroxycortisol and 18-oxocortisol.
  • Aldosterone Synthase Deficiency: ((ENDO2026)): Caused by mutations in CYP11B2, presenting with salt-wasting, hyperkalemia, metabolic acidosis, high PRA, and inappropriately low aldosterone (while cortisol synthesis is intact).
  • Primary Aldosteronism: ((ENDO2027)): Characterized by autonomous aldosterone secretion (fails to suppress with saline loading or fludrocortisone) and chronically suppressed renin that fails to rise with salt restriction.

Bone, Calcium, and Endocrine Neoplasia

  • Pseudohypoparathyroidism vs. PPHP: ((ENDO2021)): - PHP Ia: Maternally inherited GNAS mutation causing Albright hereditary osteodystrophy (AHO) + multi-hormone resistance (including PTH). - PPHP (Pseudopseudohypoparathyroidism): Paternally inherited GNAS mutation causing AHO phenotype and reduced Gs$\alpha$ activity, but normal calcium/phosphorus and absent PTH resistance.
  • Williams Syndrome: ((ENDO2022)): Deletion at chromosome 7q11.23 (elastin gene) presenting with elfin facies, supravalvular aortic stenosis, "cocktail party" personality, and hypercalcemia (occurring in ~15%, often during the first 24 months).
  • Multiple Endocrine Neoplasia (MEN) Syndromes: ((((ENDO2031)) · ((ENDO2032)))):
  • MEN 1: (MEN1 gene): Primary hyperparathyroidism, pituitary adenoma, pancreatic neuroendocrine tumors (insulinoma), and adrenal cortical tumors.
  • MEN 2B: (RET gene): Medullary thyroid carcinoma, bilateral pheochromocytomas, mucosal neuromas (lips/tongue), intestinal ganglioneuromatosis, and marfanoid habitus (hyperparathyroidism is absent).
  • HDR Syndrome: ((ENDO2033)): Hypoparathyroidism, sensorineural deafness, and renal dysplasia caused by GATA3 mutations.
  • Acrodysostosis: ((ENDO2034)): PDE4D-related acrodysostosis causes short stature and brachydactyly without significant hormone resistance, whereas PRKAR1A-related acrodysostosis features robust hormone (PTH) resistance.
  • Familial Hypocalciuric Hypercalcemia (FHH Type 1): ((ENDO2035)): Caused by heterozygous inactivating mutations in CASR, presenting with persistent mild hypercalcemic, normal/high-normal PTH, high-normal magnesium, and a calcium-to-creatinine clearance ratio <0.01. Parathyroidectomy is ineffective.

Adrenal Disorders & Congenital Adrenal Hyperplasia (CAH)

  • Autoimmune Addison Disease & Schmidt Syndrome: ((ENDO2036)): Characterized by progressive fatigue, weight loss, salt craving, hyperpigmentation, low morning cortisol, and markedly elevated ACTH. The most commonly identified biochemically defined autoantigen is 21-hydroxylase (CYP21A2). When combined with autoimmune thyroid disease (positive thyroid peroxidase antibodies), it constitutes Schmidt syndrome within autoimmune polyendocrinopathy syndrome type 2 (APS-2). Isolated cortisol deficiency can appear early, preserving normal potassium and renin/aldosterone ((ENDO2036)). Distractor: Antibodies to cholesterol side-chain cleavage enzyme, ACTH receptor, or 17α-hydroxylase are not the primary target in autoimmune Addison disease ((ENDO2036)).
  • Drug Interactions in Adrenal Insufficiency: ((ENDO2037)): Rifampicin induces hepatic steroid-metabolizing enzymes, accelerates clearance, and reduces bioavailability of hydrocortisone, precipitating adrenal crisis despite compliance ((ENDO2037)). Distractor: Ketoconazole inhibits endogenous cortisol synthesis rather than accelerating clearance ((ENDO2037)).
  • P450 Oxidoreductase Deficiency (PORD): ((ENDO2038)): Caused by POR gene mutations. Features a mixed steroidogenic pattern with elevated 17-hydroxyprogesterone and reduced DHEAS/androstenedione ((ENDO2038)). 46,XX fetuses show virilization due to alternative androgen pathways, while 46,XY fetuses have undervirilization (micropenis/hypospadias) due to impaired CYP17A1 ((ENDO2038)). Uniquely associated with Antley-Bixler skeletal syndrome (craniosynostosis, radiohumeral synostosis, bowed femora) ((ENDO2038)).
  • Congenital Lipoid Adrenal Hyperplasia (STAR Deficiency): ((ENDO2039)): Caused by STAR mutations impairing cholesterol transport into mitochondria. Results in severe salt-wasting, profoundly reduced steroids across all pathways (glucocorticoids, mineralocorticoids, sex steroids), complete undervirilization in 46,XY infants, and bilaterally enlarged lipid-laden adrenals ((ENDO2039)).
  • 3β-Hydroxysteroid Dehydrogenase Deficiency: ((ENDO2040)): Impairs conversion of $\Delta^5$ to $\Delta^4$ steroids, leading to elevated 17-hydroxypregnenolone and DHEA ((ENDO2040)). Causes salt-wasting and ambiguous genitalia in both 46,XX and 46,XY infants ((ENDO2040)). Long-term management requires surgical reconstruction and hormone replacement according to the established sex of rearing ((ENDO2040)).
  • 21-Hydroxylase Deficiency Genotype-Phenotype Correlation: ((ENDO2041)): The phenotype corresponds to the less severely affected (mildest) allele ((ENDO2041)). A compound heterozygote for a CYP21A2 deletion (null activity $\rightarrow$ salt-wasting) and a P30L variant (20–50% residual activity) manifests the nonclassic phenotype ((ENDO2041)).
  • Monitoring 21-Hydroxylase Deficiency: ((ENDO2042)): Early morning 17-hydroxyprogesterone values that are persistently low-normal indicate excessive glucocorticoid treatment with undue suppression of adrenal steroidogenesis, risking growth impairment and weight gain ((ENDO2042)). Desirable levels are high-normal or several times normal before the morning dose ((ENDO2042)).
  • Testicular Adrenal Rest Tumors (TART): ((ENDO2043)): Benign, ACTH-responsive lesions seen in males with poorly controlled CAH. Initial management is increasing glucocorticoid therapy to suppress ACTH and reduce tumor size, protecting spermatogenesis ((ENDO2043)). Surgery or orchiectomy are reserved for refractory cases ((ENDO2043)).
  • Carney Complex: ((ENDO2044)): Autosomal dominant syndrome caused by PRKAR1A mutations. Characterized by adrenal adenoma / primary pigmented nodular adrenal disease (PPNAD), cardiac/extracardiac myxomas, spotty skin pigmentation (lentigines), and large-cell calcifying Sertoli cell tumors ((ENDO2044)).
  • Bilateral Adrenal Calcification in Childhood: ((ENDO2062)): Extensive bilateral calcification is classically seen in Wolman disease (lysosomal acid lipase deficiency), severe bilateral hemorrhage, or Waterhouse-Friderichsen syndrome ((ENDO2062)). Distractor: Neuroblastoma, adrenocortical carcinoma, and pheochromocytoma typically produce unilateral calcifications secondary to intratumoral hemorrhage or necrosis ((ENDO2062)). Primary pigmented nodular adrenocortical disease (PPNAD) does not characteristically cause extensive calcification ((ENDO2062)).

Disorders of Sex Development (DSD) & Turner Syndrome

  • Testicular Regression Syndrome (Vanishing Testes): ((ENDO2048)): 46,XY infant with normal male external genitalia (proving early fetal testosterone action), nonpalpable testes, elevated LH/FSH, undetectable AMH, and no testosterone response to hCGstimulation ((ENDO2048)). Caused by vascular accident or fetal testicular torsion ((ENDO2048)).
  • Aromatase Deficiency: ((ENDO2050)): Caused by CYP19A1 mutations. 46,XX individuals present with congenital clitoromegaly (maternal/fetal androgen excess), primary amenorrhea, absent breast development, hypergonadotropic hypogonadism, elevated androgens, and markedly reduced estradiol with normal blood pressure and electrolytes ((ENDO2050)).
  • Swyer Syndrome (46,XY Pure Gonadal Dysgenesis): ((ENDO2051)): 46,XY karyotype presenting with female external genitalia, retained Müllerian structures (uterus present), hypergonadotropic hypogonadism, and primary amenorrhea with absent breast development ((ENDO2051)). Streak gonads must be removed due to high malignancy risk (gonadoblastoma) ((ENDO2051)).
  • Mixed Gonadal Dysgenesis: ((ENDO2064)): Most commonly associated with a 45,X/46,XY mosaic karyotype and atypical external genitalia (phallus, severe hypospadias, fused/bifid scrotum) ((ENDO2064)). Characterized by a dysgenetic testis on one side and a streak gonad on the other, with asymmetric AMH production permitting unilateral persistence of a Müllerian structure (hemiuterus/fallopian tube) ((ENDO2064)).

Pediatric Endocrinology & Tumors

  • Cushing Syndrome Evaluation & Management: ((((ENDO2045)) · ((ENDO2046)))): - ACTH <10 pg/mL indicates ACTH-independent disease (adrenal imaging); >20 pg/mL indicates ACTH-dependent Cushing disease; values between 10–20 pg/mL fall into the indeterminate "gray zone" requiring a CRH stimulation test before localization ((ENDO2045)). Pituitary microincidentalomas ($\le 5\text{ mm}$) are common and require biochemical confirmation ((ENDO2045)). - Preoperatively for severe hypercortisolism, use ketoconazole to inhibit adrenal steroidogenesis and reduce morbidity; it does not treat the pituitary adenoma and requires liver function monitoring ((ENDO2046)).
  • Pheochromocytoma Diagnosis & Syndromic Associations: ((((ENDO2047)) · ((ENDO2063)))): - Preferred biochemical testing: Plasma free metanephrines and urinary fractionated metanephrines ((ENDO2047)). Avoid acetaminophen (interferes with normetanephrine immunoassays) and caffeine ((ENDO2047)). Urinary catecholamines are predominantly norepinephrine in children ((ENDO2047)). - Bilateral pheochromocytomas with pancreatic cysts are hallmark features of von Hippel-Lindau (VHL) syndrome ((ENDO2063)).
  • McCune-Albright Syndrome: ((ENDO2061)): Triad of polyostotic fibrous dysplasia (exhibiting the Shepherd's crook deformity and ground-glass trabecular matrix on X-ray), café-au-lait spots with irregular "coast of Maine" borders, and autonomous endocrine hyperfunction (most commonly gonadotropin-independent precocious puberty) ((ENDO2061)).
  • Beckwith-Wiedemann Syndrome (BWS): ((ENDO2060)): Overgrowth syndrome driven by 11p15 imprinting defects. Classic triad of macroglossia, organomegaly, and hemihypertrophy, complicated by neonatal hyperinsulinemic hypoglycemia and high risk of embryonal tumors, most commonly hepatoblastoma and Wilms tumor in neonates ((ENDO2060)).

Diabetes Mellitus & Chromosomal Aneuploidies

  • Trisomy X (47,XXX): ((ENDO2049)): Most common sex chromosome aneuploidy in females. Features tall stature, normal sexual development and fertility, speech/language delays, learning difficulties, and reduced amygdala volumes on MRI ((ENDO2049)).
  • Turner Syndrome Risks: ((ENDO2059)): Characterized by short stature, webbed neck, and shield chest. Associated with autoimmune hypothyroidism (Hashimoto thyroiditis) and celiac disease, as well as systemic hypertension (often renal/coarctation-related) ((ENDO2059)). Pheochromocytoma is **not** a recognized feature of Turner syndrome ((ENDO2059)).
  • Neonatal Diabetes Mellitus: ((ENDO2053)): Diabetes diagnosed before 6 months of age mandates genetic testing for transient and permanent neonatal diabetes (e.g., KCNJ11, ABCC8 mutations), as autoimmune etiology is rare and pathogenic variants may allow transition from insulin to oral sulfonylureas ((ENDO2053)).
  • Type 1 Diabetes Prevention: ((((ENDO204)) · ((ENDO2052)))): - HLA class I allele HLA-B39 confers high risk and younger onset for type 1 diabetes ((ENDO2052)). - Teplizumab (anti-CD3 monoclonal antibody) delays progression from Stage 2 T1D (two or more islet autoantibodies with dysglycemia, normal fasting glucose) to clinical Stage 3 disease in patients $\ge 8$ years old ((ENDO2054)).
  • Diabetic Ketoacidosis (DKA) Management: ((ENDO2055)): When blood glucose reaches 250–300 mg/dL during insulin therapy (0.05–0.1 unit/kg/hr), add 5% dextrose to IV fluids while continuing the insulin infusion to clear ketonemia and acidosis safely without causing hypoglycemia ((ENDO2055)).
  • Maturity-Onset Diabetes of the Young (MODY): ((ENDO2056)): Suspected in non-autoimmune, non-obese youth with autosomal dominant family history. GCK-MODY (GCK sequencing) should be tested first if fasting plasma glucose is $\le 150\text{ mg/dL}$ and HbA1c is $<7.3\%$, presenting with stable mild fasting hyperglycemia since childhood and low microvascular risk ((ENDO2056)).